Agilon Health, Inc. (NYSE:AGL) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Agilon Health, Inc. (NYSE:AGL) have earned a consensus recommendation of “Hold” from the fifteen analysts that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $45.0455.

Several equities analysts have recently commented on AGL shares. TD Cowen restated a “hold” rating and set a $55.00 price target (up from $17.00) on shares of Agilon Health in a research note on Monday. JPMorgan Chase & Co. cut shares of Agilon Health from a “neutral” rating to an “underweight” rating and set a $21.00 target price on the stock. in a report on Monday, May 4th. Robert W. Baird raised their target price on shares of Agilon Health from $20.00 to $35.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Citigroup restated a “neutral” rating and issued a $80.00 price target (up from $18.75) on shares of Agilon Health in a report on Friday. Finally, Barclays lowered their price target on shares of Agilon Health from $25.00 to $12.50 and set an “underweight” rating for the company in a research report on Friday, February 27th.

Agilon Health Trading Up 4.5%

Shares of AGL opened at $82.05 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a market capitalization of $1.37 billion, a PE ratio of -3.81 and a beta of 2.29. The company’s fifty day moving average is $25.34 and its 200 day moving average is $20.19. Agilon Health has a fifty-two week low of $7.48 and a fifty-two week high of $84.90.

Agilon Health (NYSE:AGL) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.04 by $0.76. The firm had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.38 billion. Agilon Health had a negative net margin of 6.09% and a negative return on equity of 146.03%. Sell-side analysts expect that Agilon Health will post -4.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wealthcare Advisory Partners LLC bought a new stake in Agilon Health during the third quarter valued at about $26,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Agilon Health during the third quarter valued at about $34,000. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Agilon Health during the third quarter valued at about $37,000. Tower Research Capital LLC TRC boosted its holdings in shares of Agilon Health by 214.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 37,079 shares of the company’s stock valued at $85,000 after buying an additional 25,270 shares in the last quarter. Finally, Independent Advisor Alliance purchased a new position in shares of Agilon Health in the 3rd quarter worth approximately $39,000.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.